

S1 Table. Univariate analysis of variables correlated to survival

Endpoint	Factor	HR (95% CI)	p-value
OS	Age	1.33 (0.90-1.98)	0.157
	Sex	1.26 (0.80-1.97)	0.317
	T stage	0.95 (0.72-1.25)	0.710
	N stage	1.58 (1.21-2.05)	0.001
	Family history	1.19 (0.67-2.14)	0.553
	Smoking	1.33 (0.88-1.99)	0.167
	Pre-EBV DNA	2.05 (1.38-3.06)	< 0.001
	VCA-IgA	0.74 (0.48-1.14)	0.175
	EA-IgA	0.79 (0.53-1.20)	0.268
	Pre-ALC	1.46 (0.95-2.26)	0.085
	Mini-ALC	2.55 (1.36-4.78)	0.003
	Post-ALC	1.54 (1.02-2.33)	0.040
	Post3m-ALC	2.17 (1.44-3.26)	< 0.001
	Min-ALC combined with post3m-ALC	4.04 (2.00-8.14)	< 0.001
	ALC ^{a)}	0.996 (0.991-0.999)	0.037
	PFS	Age	1.16 (0.82-1.64)
Sex		1.22 (0.83-1.80)	0.310
T stage		1.06 (0.83-1.37)	0.624
N stage		1.50 (1.20-1.89)	< 0.001
Family history		1.11 (0.64-1.89)	0.717
Smoking		1.28 (0.90-1.84)	0.172
Pre-EBV DNA		2.13 (1.50-3.02)	< 0.001
VCA-IgA		0.97 (0.65-1.45)	0.870
EA-IgA		1.01 (0.70-1.46)	0.970
Pre-ALC		1.45 (0.99-2.13)	0.060
Mini-ALC		2.02 (1.23-3.32)	0.006
Post-ALC		1.31 (0.92-1.864)	0.137
Post3m-ALC		2.06 (1.43-2.96)	< 0.001
Min-ALC combined with post3m-ALC		3.14 (1.79-5.49)	< 0.001
ALC ^{a)}		0.993 (0.988-0.998)	0.007
DMFS		Age	0.99 (0.64-1.53)
	Sex	1.53 (0.92-2.56)	0.104
	T stage	1.11 (0.82-1.52)	0.501
	N stage	1.52 (1.14-2.02)	0.004
	Family history	1.44 (0.78-2.66)	0.242
	Smoking	1.14 (0.73-1.79)	0.571
	Pre-EBV DNA	2.43 (1.57-3.76)	< 0.001
	VCA-IgA	0.95 (0.57-1.57)	0.842
	EA-IgA	1.13 (0.71-1.81)	0.613
	Pre-ALC	1.45 (0.89-2.34)	0.133
	Mini-ALC	2.65 (1.32-5.29)	0.006
	Post-ALC	1.59 (1.01-2.51)	0.044
	Post3m-ALC	2.17 (1.38-3.40)	0.001
	Min-ALC combined with post3m-ALC	4.28 (1.96-9.36)	< 0.001
	ALC ^{a)}	0.993 (0.986-0.999)	0.032

HR, hazard ratio; CI, confidence interval; OS, overall survival; EBV, Epstein-Barr virus; VCA, viral capsid antigen; EA, early antigen; pre-ALC, absolute lymphocyte counts before treatment; mini-ALC, minimum absolute lymphocyte counts during treatment; post-ALC, absolute lymphocyte counts after completion of treatment; post3m-ALC, absolute lymphocyte counts after 3 months completion of treatment; ALC, absolute lymphocyte counts; PFS, progression-free survival; DMFS, distant metastasis-free survival. ^{a)}A Cox regression model using ALC as a time-dependent variable.